Ascendis Pharma A/S (NASDAQ:ASND) is reporting second quarter financial results on Thursday 27th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ASND is expected to report 2Q20 loss of $ 1.71 per share from revenue of $ 2.53 million.
For the full year, analysts anticipate top line of $ 11.31 million, while looking forward to loss of $ 6.68 per share bottom line.
Previous Quarter Performance
Ascendis Pharma A/S unwinded loss for the first quarter of $ 1.46 per share, from the revenue of $ 2.45 million. The quarterly revenues down 59.30 percent compared with the same quarter last year. According to street consensus, ASND was expected to report 1Q20 loss of $ 1.50 per share from revenue of $ 2.07 million. The bottom line results beat street analysts by $ 0.04 or 2.67 percent, at the same time, top line results outshined analysts by $ 0.38 million or 18.36 percent.
Stock Performance
Shares of Ascendis Pharma A/S traded low $ -0.55 or -0.39 percent on Wednesday, reaching $ 139.47 with volume of 149.80 thousand shares. Ascendis Pharma A/S has traded high as $ 140.67 and has cracked $ 137.57 on the downward trend
The closing price of $ 139.47, representing a 55.47 % increase from the 52 week low of $ 90.06 and a 11.9 % decrease over the 52 week high of $ 158.93.
The company has a market capital of $ 7.42 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th July 2020, maintained by Morgan Stanley at Overweight rating, with $ 177.00 target price.
Conference Call
Ascendis Pharma A/S will be hosting a conference call at 4:30 PM eastern time on 27th August 2020, to discuss its 2Q20 financial results with the investment community. The participants may dial, 844-290-3904 Toll Free, (United States) or 574-990-1036 Outside U.S., and the passcode is 9987362 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website edge.media-server.com/mmc/p/w7hnzp6j
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies.
